Quercetin and Improved Pulmonary Function

Doses used in studies

Time to effect

Median: 3 weeks · IQR 3 weeks–3 weeks · Range 3 weeks–3 weeks — Reported in 1 of 1 study

Safety in these studies

anxietyIncreased risk4/6 vs 0/6
Sleep disturbances and anxiety were disproportionately represented in the D+Q arm (4/6 vs 0/6).
from: Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I,
sleep disturbancesIncreased risk4/6 vs 0/6
Sleep disturbances and anxiety were disproportionately represented in the D+Q arm (4/6 vs 0/6).
from: Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I,
Overall tolerabilityReported
While the placebo arm reported fewer overall non-serious AEs (65 vs 22), there were no serious adverse events related to D+Q.
from: Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I,

1 of 1 paper

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability.